E-Mail:
Password:
Home | Stock Market Blogs | Financial Tools | Sign Up Free
 

gear headHow cool is this? Shampoo for men in a quart of oil bottle!

Click the banner to get some now and tell the little lady to throw that other stuff in the trash!
VIVUS  
VIVUS
VVUSLast: $5.26 ($+0.07)Volume: 2,661,863Last Trade: 8/5/2010 5:20:02 PM
Today

Today | Last 7 Days | 1 Month | 3 Month | 6 Month | 1 Year
 Options
Quote |  Alerts | | Free Newsletter
 
 Detailed Quote
NASDAQ:VVUS $5.26 ($+0.07 +1.3487%)
Industry: Industrial Services Sector: Research Support Services
Open: 5.23 Previous Close: 5.19
Day's High: 5.30 Day's Low: 5.11
52-Week High: 6.55 52-Week Low: 3.85
 
Bid: 5.24 / 12,800 Ask: 5.25 / 2,200
Volume: 2,661,863 Outstanding: 58,658,748
Market Cap: $349 M
VIVUS Profile
Vivus is a pharmaceutical company engaged in the research, development and commercialization of products to treat obesity, post-menopausal, and sexual health in women and men. As of Dec 31 2006, Co. had four research and development programs targeting obesity and sexual health, which include: Qnexa , for treating obesity; EvaMist , to treat vasomotor symptoms associated with menopause; Testosterone MDTS , which is being developed to treat hypoactive sexual desire disorder; and Avanafil , which is being developed for the treatment of erectile dysfunction. In addition, Co. also markets MUSE as a prescription product for the treatment of erectile dysfunction.
 VIVUS News & Press Releases

VIVUS Comments on FDA Advisory Committee Panel Meeting on QNEXA (phentermine/topiramate) Controlled
MOUNTAIN VIEW, Calif. , July 15 /PRNewswire-FirstCall/ -- VIVUS, Inc. ( VVUS ) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted against the f... [more]

Positive Results From Phase 3 Study of Avanafil in Erectile Dysfunction Presented at AUA Annual Meet
MOUNTAIN VIEW, Calif. , June 1 /PRNewswire-FirstCall/ -- VIVUS, Inc. ( VVUS ) today announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the inv... [more]

VIVUS Grants Stock Option to New Senior Vice President and Chief Commercial Officer
MOUNTAIN VIEW, Calif. , May 4 /PRNewswire-FirstCall/ -- VIVUS, Inc. ( VVUS ) today announced that, in accordance with NASDAQ Listing Rule 5635, Michael P. Miller , the Company's new senior vice president and chie... [more]

Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientif
MOUNTAIN VIEW, Calif., Oct. 29 /PRNewswire-FirstCall/ -- VIVUS, Inc. ( VVUS ) today announced that additional data on Qnexa(TM), an investigational drug candidate for obesity, was presented at the 27th a... [more]

VIVUS Announces Pricing of Public Offering of Common Stock
500 Internal Server Error Internal Server Error The server encountered an internal error or misconfiguration and was unable to complete your request.<... [more]

VIVUS Announces Proposed Public Offering of Common Stock
MOUNTAIN VIEW, Calif., Sept. 16 /PRNewswire-FirstCall/ -- VIVUS, Inc. ( VVUS ), announced today that it is offering to sell, subject to market and other conditions, 9,000,000 shares of its common... [more]

VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average W
MOUNTAIN VIEW, Calif., Sept. 9 /PRNewswire-FirstCall/ -- VIVUS, Inc. ( VVUS ) today announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQU... [more]

VIVUS Announces Date of Fourth Quarter and Full Year 2008 Financial Results and Conference Call
MOUNTAIN VIEW, Calif., March 5, 2009 (GLOBE NEWSWIRE) -- VIVUS, Inc. ( VVUS ), a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health, today announced that it will r... [more]

VIVUS to Present at the 2008 UBS Life Sciences Conference
VIVUS, Inc. ( VVUS ), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Peter Tam... [more]

VIVUS Appoints Charles J. Casamento to the Board of Directors
VIVUS, Inc. ( VVUS ) announced today that it has appointed Charles J. Casamento to serve on the Board of Directors. Mr. Casamento has over 38 years of experien... [more]


Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign UpCopyright 2014
SmallCapWatch, LLC.
Never invest based soley on information from this website or our e-mail and IM alerts